Key Highlights
● Second-quarter Revenue was $587.3 million versus $621.4 million, organic revenue fell 1.5% and adjusted EBITDA Margin was 42.1%.
● The net loss of $268.6 million included a $221.7 million non-cash Goodwill impairment, while adjusted Net Income was $123.1 million.
● Total Debt fell $218.4 million to $4,251.5 million, helped by a $100.0 million accelerated repayment and discounted note repurchases.
● Life Sciences and Healthcare moves to discontinued operations in the third quarter, with no buyer, price or terms disclosed.
Clarivate Plc (NYSE:CLVT), the information services and analytics provider, is midway through a restructuring that combines a divestiture of its Life Sciences and Healthcare segment, cost actions under a Value Creation Plan and continued debt reduction. Its second-quarter 2026 results, released in late July, showed softer revenue, a large non-cash Impairment and steady adjusted profitability. Because its latest release discloses no common dividend, the Balance Sheet is arguably the more relevant lens for Capital allocation.
Latest Company Context
For the second quarter, Clarivate reported revenue of $587.3 million, down from $621.4 million a year earlier, with organic revenue down 1.5%. The net loss was $268.6 million, or $0.42 per diluted share, including a $221.7 million non-cash goodwill impairment. Adjusted net income was $123.1 million, or $0.19 per share, and adjusted EBITDA was $247.2 million, a 42.1% margin. Operating Cash Flow was $98.7 million and free cash flow $44.0 million. Total debt was $4,251.5 million at June 30, down $218.4 million, after a $100.0 million accelerated repayment fully redeemed notes due November 2026 and a repurchase of $117.6 million of 2028 and 2029 notes at about a 6% discount to par. Cash was $217.7 million. CEO Matti Shem Tov said the Value Creation Plan continues to drive meaningful progress on strategic priorities.
Key Business Drivers
Segment trends are mixed. Academia and Government revenue was $300.3 million, up 0.3% organically; Intellectual Property was $198.3 million, down 2.3%; and Life Sciences and Healthcare was $88.7 million, down 5.2%. The Life Sciences and Healthcare business, previously announced for sale, will be reported as discontinued operations from the third quarter, and management expects a more focused company with a higher Recurring Revenue mix. The release did not give the buyer, price or terms. Restructuring costs were $12.1 million in the quarter, with about $35 million expected for 2026. Management reaffirmed 2026 guidance: organic annual contract value growth of 2.0% to 3.0%, adjusted EBITDA of $980 million to $1.04 billion, adjusted diluted EPS of $0.70 to $0.80 and free cash flow of $365 million to $435 million, excluding further acquisitions or divestitures.
What Investors Should Watch
Investors may watch several items. The first is the divestiture: terms, timing and how proceeds might be applied to debt could influence the Leverage profile. A rough estimate based on the guidance midpoint suggests gross debt of roughly four times adjusted EBITDA, though this is a calculation rather than a company-reported ratio. The second is organic growth, since organic revenue declined in the quarter while full-year guidance for recurring organic revenue growth is 0.75% to 2.25%. The third is cash generation: first-half free cash flow of $122.9 million trailed the prior-year $160.6 million, so the second half may need to improve to meet the guided range. Share repurchases slowed to $18.1 million in the first half from $99.5 million a year earlier. Finally, the pace of artificial intelligence-related product adoption and the outcome of cost actions may shape margins.
A Smaller, More Focused Clarivate
Clarivate presents a company in transition, with stable adjusted margins and lower debt but declining reported revenue and a significant impairment. The quarterly results and debt reduction are reported fact, the full-year ranges are management guidance, and the outlook for leverage and growth after the divestiture depends on execution. Investors may find the third-quarter report, the first to show discontinued operations, a useful checkpoint.






Please wait processing your request...